Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.

被引：0
|
作者：
Kudchadkar, Ragini Reiney [1 ]
Gallenstein, Donna [1 ]
Martinez, Alberto J. [1 ]
Yu, Bin [1 ]
Weber, Jeffrey S. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8582
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
    Robert, Caroline
    Ascierto, Paolo Antonio
    Maio, Michele
    Hernberg, Micaela
    Schmidt, Henrik
    Waxman, Ian
    Garbe, Claus
    Lebbe, Celeste
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies
    Lesokhin, Alexander M.
    Gutierrez, Martin
    Halwani, Ahmad Sami
    Ansell, Stephen Maxted
    Armand, Philippe
    Borrello, Ivan
    Segota, Zdenka E.
    Cohen, Adam D.
    Talpaz, Moshe
    Cattry, Deepika
    Turner, Tracy
    Mezes, Maria
    Hartman, Christina
    Gupta, Ashok Kumar
    Kim, Su Young
    Wigginton, Jon M.
    Timmerman, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Murayama, Toshinori
    Chikuma, Shunsuke
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
    Motzer, R. J.
    Bono, P.
    Tomita, Y.
    Ravaud, A.
    Waxman, I.
    Gore, M. E.
    BJU INTERNATIONAL, 2013, 112 : 10 - 10
  • [25] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
  • [26] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
    Sznol, M.
    Callahan, M. K.
    Kluger, H.
    Postow, M. A.
    Burke, M.
    Hong, Q.
    Selby, M.
    Korman, A.
    Gupta, A.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
  • [27] Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up
    Drake, Charles G.
    McDermott, David F.
    Sznol, Mario
    Choueiri, Toni K.
    Kluger, Harriet M.
    Powderly, John D.
    Smith, David C.
    Sankar, Vindira
    Gutierrez, Andres A.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma.
    Hawkins, R. E.
    Dangoor, A.
    Keilholz, U.
    Schadendorf, D.
    Harris, A.
    Ottensmeier, C.
    Smyth, J.
    Hoffmnan, K.
    Anderson, R.
    Pearce, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
  • [29] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
    Kluger, H.
    Sznol, M.
    Callahan, M.
    Postow, M.
    Gordon, R.
    Segal, N. H.
    Rizvi, N.
    Lesokhin, A.
    Atkins, M. B.
    Kirkwood, J.
    Burke, M.
    Ralabate, A.
    Rivera, A.
    Kronenberg, S.
    Agunwamba, B. U.
    Feely, W.
    Hong, Q.
    Krishnan, S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma
    Weber, J. S.
    Sarnaik, A.
    Targan, S.
    Yu, B.
    Morelli, D.
    Urbas, P.
    Maker, N.
    Yellin, M.
    Nichol, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345